Engbers Elsemiek M, Timmer Jorik R, Mouden Mohamed, Knollema Siert, Jager Pieter L, Ottervanger Jan Paul
Department of Cardiology, Isala, Zwolle, the Netherlands; Department of Nuclear Medicine, Isala, Zwolle, the Netherlands.
Department of Cardiology, Isala, Zwolle, the Netherlands.
Am Heart J. 2017 Apr;186:56-62. doi: 10.1016/j.ahj.2017.01.009. Epub 2017 Jan 19.
The impact of coronary artery calcium (CAC) scoring on subsequent changes in cardiovascular medication use in symptomatic patients with normal myocardial perfusion imaging (MPI) findings is not well established. The aim of the current study was to evaluate changes in aspirin and statin use in patients suspected for coronary artery disease after CAC scoring and normal single photon emission computed tomography (SPECT) MPI.
In the current study, 1,033 stable symptomatic patients without a known history of coronary artery disease with normal SPECT MPI who underwent concomitant CAC scoring were included. All patients had a clinical indication for imaging, mainly atypical chest pain and dyspnea, and were referred from the outpatient clinic of our hospital. Data regarding posttest medication change (either starting or discontinuation of aspirin and statin therapy at the subsequent outpatient visit) were retrospectively collected. Patients were categorized into 4 groups based on their CAC score.
Mean age of the patients was 61±11 years and 39% were male. At baseline, 35% of the patients used aspirin and 39% used statin. In patients with CAC scores 0, 1-99, 100-399, and ≥400, aspirin was started in 1%, 4%, 9%, and 9%, respectively, and statin was started in 0%, 7%, 18%, and 24% of the patients, respectively (P<.001). Aspirin was discontinued in 19%, 11%, 7%, and 1% and statin was discontinued in 8%, 6%, 2%, and 0% (P<.001) of the patients in these respective CAC score categories. After correction for differences in risk factors and baseline medication use, increased CAC was independently associated with posttest aspirin (odds ratio 4.6, 11.2, and 27.1 for CAC scores 1-99, 100-399, and ≥400, respectively; P<.001) and statin use (odds ratio 4.4, 19.4, and 60.9 for CAC scores 1-99, 100-399, and ≥400, respectively; P<.001).
Higher CAC scores are associated with the initiation of aspirin and statin therapy in patients with normal SPECT MPI. In patients with lower CAC scores, discontinuation of cardioprotective medication is more likely. CAC score is independently associated with posttest statin and aspirin use.
对于有症状且心肌灌注成像(MPI)结果正常的患者,冠状动脉钙化(CAC)评分对后续心血管药物使用变化的影响尚未明确。本研究的目的是评估在进行CAC评分且单光子发射计算机断层扫描(SPECT)MPI结果正常的疑似冠心病患者中,阿司匹林和他汀类药物使用的变化情况。
在本研究中,纳入了1033例无冠心病病史、SPECT MPI结果正常的稳定有症状患者,这些患者同时进行了CAC评分。所有患者都有影像学检查的临床指征,主要是非典型胸痛和呼吸困难,均来自我院门诊。回顾性收集关于检查后药物变化的数据(即在随后的门诊就诊时开始或停止使用阿司匹林和他汀类药物治疗)。根据CAC评分将患者分为4组。
患者的平均年龄为61±11岁,男性占39%。基线时,35%的患者使用阿司匹林,39%的患者使用他汀类药物。在CAC评分为0、1 - 99、100 - 399和≥400的患者中,分别有1%、4%、9%和9%的患者开始使用阿司匹林,分别有0%、7%、18%和24%的患者开始使用他汀类药物(P<0.001)。在这些相应的CAC评分类别中,分别有19%、11%、7%和1%的患者停用阿司匹林,有8%、6%、2%和0%的患者停用他汀类药物(P<0.001)。在校正了危险因素和基线药物使用的差异后,CAC增加与检查后阿司匹林使用独立相关(CAC评分为1 - 99、100 - 399和≥400时,比值比分别为4.6、11.2和27.1;P<0.001)以及他汀类药物使用独立相关(CAC评分为1 - 99、100 - 399和≥400时,比值比分别为4.4、19.4和60.9;P<0.001)。
较高的CAC评分与SPECT MPI正常的患者开始使用阿司匹林和他汀类药物治疗相关。在CAC评分较低的患者中,更有可能停用心脏保护药物。CAC评分与检查后他汀类药物和阿司匹林的使用独立相关。